$29.45
0.81% yesterday
Nasdaq, Nov 25, 10:01 pm CET
ISIN
US26817R1086
Symbol
DYN
Sector
Industry

Dyne Therapeutics Inc Stock price

$29.45
-1.28 4.17% 1M
-1.77 5.67% 6M
+16.15 121.43% YTD
+18.79 176.27% 1Y
+13.59 85.69% 3Y
+5.55 23.22% 5Y
+5.55 23.22% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.24 0.81%
ISIN
US26817R1086
Symbol
DYN
Sector
Industry

Key metrics

Market capitalization $3.00b
Enterprise Value $2.30b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 4.25
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-314.47m
Free Cash Flow (TTM) Free Cash Flow $-244.42m
Cash position $723.67m
EPS (TTM) EPS $-3.56
P/E forward negative
Short interest 11.79%
Show more

Is Dyne Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Dyne Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Dyne Therapeutics Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Dyne Therapeutics Inc forecast:

Buy
90%
Hold
10%

Financial data from Dyne Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 1.75 1.75
30% 30%
-
-1.75 -1.75
30% 30%
-
- Selling and Administrative Expenses 53 53
114% 114%
-
- Research and Development Expense 258 258
40% 40%
-
-313 -313
47% 47%
-
- Depreciation and Amortization 1.75 1.75
30% 30%
-
EBIT (Operating Income) EBIT -314 -314
47% 47%
-
Net Profit -295 -295
42% 42%
-

In millions USD.

Don't miss a Thing! We will send you all news about Dyne Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Dyne Therapeutics Inc Stock News

Positive
Seeking Alpha
15 days ago
Dyne Therapeutics, Inc. develops treatments for muscle diseases using its FORCE platform, with promising candidates DYNE-101 and DYNE-251 targeting DM1 and DMD, respectively. DYNE-251 shows significant improvement over Sarepta's Eteplirsen in Phase 1/2 trials, potentially accelerating approval and boosting DYN's stock. Key risks include executive reshuffling and potential hidden issues with IP,...
Neutral
GlobeNewsWire
19 days ago
WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc.  (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present at the following upcoming investor conferences:
Neutral
GlobeNewsWire
about 2 months ago
- Presentations Will Feature Recent Clinical Data From DYNE-251 and DYNE-101 as Well as Preclinical Data in FSHD and Pompe Disease -
More Dyne Therapeutics Inc News

Company Profile

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Head office United States
CEO John Cox
Employees 141
Founded 2017
Website www.dyne-tx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today